Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03328273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Jan 9, 2026, no change to tracked fieldsv27-v29
  2. Enrollment target: 11 to 12v26
  3. 3 versions Re-verified since Nov 18, 2024, no change to tracked fieldsv23-v25
  4. Completion date: Jun 28, 2024 to Aug 26, 2026v22
  5. Completion date: Jun 30, 2023 to Jun 28, 2024v21
Show 19 earlier versionsHide 19 earlier versions
  1. Re-verified, no change to tracked fieldsv20
  2. Start date: Jul 15, 2020 to Jan 31, 2018v19
  3. 2 versions Re-verified since Sep 8, 2022, no change to tracked fieldsv17-v18
  4. Start date: Jan 31, 2018 to Jul 15, 2020v16
  5. Completion date: Dec 31, 2021 to Jun 30, 2023v15
  6. Phase: Phase 1/2 to Phase 1 Primary completion date changed from estimate of Dec 31, 2021 to Sep 7, 2021v14 Show 1 more changeShow less
    • Primary completion date changed from estimate of Dec 31, 2021 to Sep 7, 2021
  7. Enrollment target: 12 to 11 Primary and study completion dates: Oct 21, 2021 to Dec 31, 2021v13 Show 1 more changeShow less
    • Primary and study completion dates: Oct 21, 2021 to Dec 31, 2021
  8. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 50 to confirmed 12 · Study sites: 14 to 11 · Primary and study completion dates: Sep 26, 2022 to Oct 21, 2021v12 Show 3 more changesShow less
    • Enrollment target: estimated 50 to confirmed 12
    • Study sites: 14 to 11
    • Primary and study completion dates: Sep 26, 2022 to Oct 21, 2021
  9. Re-verified, no change to tracked fieldsv11
  10. Site details revised at 5 of 14 sitesv10
  11. Primary completion date: Feb 2022 to Sep 26, 2022 Enrollment target: 62 to 50 · Study sites: 10 to 14 · Completion date: Mar 2022 to Sep 26, 2022 · 1 morev9 Show 4 more changesShow less
    • Enrollment target: 62 to 50
    • Study sites: 10 to 14
    • Completion date: Mar 2022 to Sep 26, 2022
    • Study description expanded, about 90 words

    See this version in full on ClinicalTrials.gov ↗

  12. Primary completion date: Jan 2020 to Feb 2022 Study sites: 5 to 10 · Completion date: Apr 2020 to Mar 2022 · Interventions: AZD6738 (Drug), acalabrutinib (Drug) to Acalabrutinib (Drug), Ceralasertib (Drug) · 1 morev8 Show 4 more changesShow less
    • Study sites: 5 to 10
    • Completion date: Apr 2020 to Mar 2022
    • Interventions: AZD6738 (Drug), acalabrutinib (Drug) to Acalabrutinib (Drug), Ceralasertib (Drug)
    • Eligibility criteria expanded, about 140 words

    See this version in full on ClinicalTrials.gov ↗

  13. 2 versions Re-verified since Nov 21, 2018, no change to tracked fieldsv6-v7
  14. Study sites: 3 to 5v5
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Start date changed from estimate of Nov 2017 to Jan 31, 2018v4 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Start date changed from estimate of Nov 2017 to Jan 31, 2018
  16. 2 versions Re-verified since Oct 31, 2017, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.
Trial Details
NCT Number NCT03328273
Lead Sponsor Acerta Pharma BV
Conditions Chronic Lymphocytic Leukemia
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov